Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3484]

Immune cells use previously unknown pathway to eliminate AML

Immune cells use previously unknown pathway to eliminate AML

ECOG-ACRIN ENDURANCE trial findings provide the first randomised evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

ECOG-ACRIN ENDURANCE trial findings provide the first randomised evidence on the optimal duration of lenalidomide...

Immune ecotypes may explain multiple myeloma outcomes missed by disease staging

Immune ecotypes may explain multiple myeloma outcomes missed by disease staging

Combination treatment harnesses cellular recycling system to fight multiple myeloma

Combination treatment harnesses cellular recycling system to fight multiple myeloma

IU study finds obesity 'fuels' leukaemia, but a combo using popular weight-loss drugs may stop it

IU study finds obesity 'fuels' leukaemia, but a combo using popular weight-loss drugs may stop it

Novel microenvironment-targeted therapy for bone marrow recovery after injury

Novel microenvironment-targeted therapy for bone marrow recovery after injury

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

B-cell lymphoma: Cause of high-risk disease discovered

B-cell lymphoma: Cause of high-risk disease discovered

More from ecancer